Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 16/20 | 0.54 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6000583 | 1.00 | PTGER4 (0.54) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6001294 | 0.88 | PTGER4 (0.54) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6000804 | 0.88 | PTGER4 (0.53) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6001302 | 0.88 | PTGER4 (0.54) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6000812 | 0.88 | PTGER4 (0.53) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6000606 | 0.87 | PTGER4 (0.40) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6000601 | 0.87 | PTGER4 (0.40) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6001219 | 0.85 | PTGER4 (0.52) | PTGER4PTGER3PTGER2 | |
| SCHEMBL6001226 | 0.85 | PTGER4 (0.52) | PTGER4PTGER3PTGER2 | |
| SCHEMBL5999586 | 0.84 | PTGER4 (0.44) | PTGER4PTGER3PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060258726-A1 | 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases | MERCK FROSST CANADA LTD. (CA) | 2006-11-16 | — | — | US | claimed |
| US-20060258726-A1 | 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases | MERCK FROSST CANADA LTD. (CA) | 2006-11-16 | — | — | US | disclosed |
| EP-1513523-A1 | 1,5-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE AND BONE DISEASES | Merck Frosst Canada & Co. (CA) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003103664-A1 | 1,5-DISUBSTITUTED IMIDAZOLIDIN-2-ONE DERIVATIVES FOR USE AS EP4 RECEPTOR AGONISTS IN THE TREATMENT OF EYE AND BONE DISEASES | MERCK FROSST CANADA & CO. (CA) | 2003-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258726-A1 | 1,5-Disubstituted imidazolidin-2-one derivatives for use as ep4 receptor agonists in the treatment of eye and bone diseases | PTGER4, PTGER1, PTGER2 | PTGER4 1/4885PTGER3 5/4885PTGER2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.